Navigation Links
Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
Date:9/16/2008

TORONTO, Sept. 16 /PRNewswire/ - In a head to head comparison of Interface Biologics Inc. (IBI) Endexo Anti-thrombic additives versus commercially available heparin coated catheters, both products achieved significant reductions (88%) in thrombus versus the polyurethane (Carbothane(TM)) control (data on file).

"Due to the recent contamination, subsequent price increases, and safety issues for Heparin, catheter manufacturers are seeking alternative coatings for their products. Interface Biologics' Endexo(TM) anti-thrombic additives are non-drug polymers that have anti platelet properties. These polymers are compatible with a wide range of base polymers, and since they are an additive rather than a coating, afford ease of process manufacturing as well as provide both extra and intraluminal coverage, and are equivalent in thrombus reduction performance to commercially available coatings," stated Rich Sullivan, President and CEO of Interface Biologics.

The blood loop study was performed at the Medical Device Evaluation Center (MDEC) in Salt Lake City Utah. "Catheters with effective Endexo additives showed a significant reduction in thrombus versus a standard polyurethane control, and were not statistically different in antithrombotic efficacy versus a commercially available heparin coated catheter," stated Sivaprasad Sukavaneshvar, Ph.D., VP of MDEC.

About Interface Biologics Inc.

Interface Biologics is a biomaterials company located in Toronto, Canada. The company develops and manufactures novel anti-thrombic and anti-infective polymers used in medical devices for cardiovascular and urological applications.


'/>"/>
SOURCE Interface Biologics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Velos to Develop Key System Interface for Clinical Research
2. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site
3. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
4. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
5. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
6. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
7. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
8. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
9. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
10. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
11. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 According to market ... and Demand Forecast to 2022 - Industry Insights by Slice ... Center and Others)" by P&S Market Research, the global ... 2015, and it is expected to grow at a CAGR ... slice type segment is expected to witness the faster growth, ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
(Date:5/3/2016)... KANSAS CITY, Mo. , May 3, 2016 ... of Kansas Medical Center,s Institute for Advancing Medical ... develop and commercialize new drugs, diagnostics and medical ... organizations provides BioNovus Innovations with rights to license, ... "This partnership ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 2016 , ... Nepenthe Laboratory Services (NLS), a premier drug monitoring and toxicology ... food item donations for Food for Lane County, and to help support awareness for ... of the assembly was to create an exciting atmosphere for the kids at Riverbend ...
(Date:5/5/2016)... ... May 05, 2016 , ... BloodHub, ... blood and service orders. Blood suppliers and their hospitals use BloodHub for ... serves 13,000 active users across 2,100 hospitals who use our platform to processes ...
(Date:5/4/2016)... (PRWEB) , ... May 05, 2016 , ... “Less than ... Jeffers, Little City Executive Director. “As one of ten non-profit organizations to participate and ... Points of Light. The ultimate benefit is that for every $1 we invest in ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... million in grants to identify, fund and implement ideas aimed at improving care ... Medicaid. , “Part of our vision for Trinity Health is to drive ...
(Date:5/4/2016)... Charlotte, NC (PRWEB) , ... May 04, 2016 ... ... platform for sleep wellness and sleep disorder management, today announced it has secured ... World Innovation Lab (WiL) and existing investors. The investment will be used by ...
Breaking Medicine News(10 mins):